Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Assertio Reports Second Quarter 2025 Financial Results
August 11, 2025 4:05 PM EDTSecond Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million
Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy
LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients needs, today reported financial results for the second quarter ended June 30, 2025.
Said Brendan OGrady, Chief Executive Officer, The... More
